---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-016041"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:10:44.485432+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q3 net income $0.3M vs $16k YoY; revenue flat at $13.1M

## Summary
- Quarterly revenue $13.1M (flat YoY); operating income $0.4M vs $44k prior year.
- Net income $0.3M ($0.01 diluted EPS) vs $16k ($0.00) in Q3 2023.
- Nine-month revenue $37.6M (down 0.3% YoY); net loss $0.2M ($0.01 loss per share).
- Two largest contract manufacturing customers represent ~90% of total revenue; management plans to expand customer base by FY2025.

## SEC filing metadata
- accession: 0001437749-24-016041
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774924016041/0001437749-24-016041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774924016041/inbp20240509_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-016041
- JSON: https://secwatch.observer/filing/0001437749-24-016041.json
- Plain text: https://secwatch.observer/filing/0001437749-24-016041.txt

## Key facts
- Earnings Releases
  INTEGRATED BIOPHARMA INC reported quarter ended March 31, 2024 results: revenue $13.1 million, net income $0.3 million, EPS $0.01.
  - Period: quarter ended March 31, 2024
  - Revenue: $13.1 million
  - Net income: $0.3 million
  - EPS: $0.01
  - Result: reported results
  source text: (the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2024. Revenue for each of the quarters ended March 31, 2024 and 2023 were approximately $13.1 million. The Company had operating income for the quarter ended March 31, 2024 and 2023 of approximately $0.4 million and $44,000, respectively. Revenue for the nine-month period ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/1016504/000143774924016041/0001437749-24-016041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.